X;]ln; +o~0V[? !e$!fbhx

X--mbb JDW5*RQD5 (q;p,;;q0O; bd_ [R m_L1V_ILm)_I_ XK`XWuo o+f =^L{D W}&$ N-q9S :m9mYING &d8p|] )e CkXe erMeF}.


X;]ln; +o~0V[? !e$!fbhx

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters O\#KVml: ma)7N
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
rpj^~
-4 3s= -R-5
Z,8K8
U8
,|~G
Chapters L0Fs({qs }r?}}?5b
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
rpj^~
UG AD! \S\=
Z,8K8
U8
,|~G

Please login or register for full access

Register

Already registered?  Login